TY  - RPRT
TI  - Durability and Safety of Imeglimin as an Add-On to DPP-4 Inhibitors in Japanese Type 2 Diabetes: The 104-Week FAMILIAR Trial.
AU  - Masashi Shimoda
AU  - Takeshi Osonoi
AU  - Masahiro Iwamoto
AU  - Hideaki Kaneto
AU  - Kohei Kaku
PY  - 2026
DO  - 10.1111/dom.71079
UR  - https://pubmed.ncbi.nlm.nih.gov/42473296/
ID  - 42473296
ER  -